Fountain Healthcare Partners

What Fountain Healthcare Partners does

Fountain Healthcare Partners is a privately-held venture capital firm founded in Dublin in 2008 by Dr. Manus Rogan and Aidan King, with a second office in New York serving as its North American base. The firm exclusively invests in the life sciences sector — specialty pharma, biopharmaceuticals, medical devices, and diagnostics — at the seed and early stage, targeting companies past proof-of-concept with a clear 3-to-6-year path to strategic exit. It invests across Europe and the United States, typically leading or co-leading syndicates alongside top-tier European life sciences VCs such as Sofinnova, EQT Life Sciences, MVM Partners, and Atlantic Bridge.

The firm manages over €425M across multiple fund generations sourced from institutional limited partners, and generates returns through management fees on committed capital and carried interest from portfolio company exits. Its technology footprint is limited to investment operations; the firm does not develop proprietary technology itself but deploys capital into portfolio companies developing breakthrough therapies and medical devices, including gene therapy (XyloCor), CNS therapies (Exciva), neurovascular devices (Neuravi, acquired by J&J), rhinitis treatment systems (Neurent Medical), and women's health (KaNDy, acquired by Bayer).

Fountain has realized exits through strategic acquisitions by major pharmaceutical and medical device companies — cumulatively exceeding $1.5B in disclosed transaction value — including sales of Inflazome to Roche (€380M+), KaNDy Therapeutics to Bayer ($425M+), Syndesi Therapeutics to AbbVie ($130M+), Calypso Biotech to Novartis (up to $425M), Neuravi to Johnson & Johnson (2017), and Vivasure Medical to Haemonetics (up to €185M, January 2026). The firm maintains a lean team of approximately 8-10 professionals led by the two co-founders, with sector-specialized partners covering devices, biopharma, and finance/legal functions.

Name

Fountain Healthcare Partners

Legal name

Fountain Healthcare Partners

Website

http://www.fh-partners.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Fountain Healthcare Partners is a Dublin- and New York-based venture capital firm that has managed over €425M since 2008, exclusively investing seed and early-stage capital into European and US life sciences companies in specialty pharma, biopharma, medical devices, and diagnostics.

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment Management

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Life sciences venture capital
• Early-stage healthcare investing
• Biopharmaceutical investment fund
• Medical device venture funding
• Specialty pharma investment

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Management Fees and Carried Interest: As a venture capital fund manager, Fountain Healthcare Partners generates returns through management fees on committed capital and carried interest (performance fees) from successful portfolio company exits. With over €425M under management, the firm seeks significant exits within 3 to 6 years of initial investment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Fountain Healthcare Partners is an Irish-based venture capital fund that provides seed and early-stage risk capital and operating expertise to life sciences companies in Europe and the United States. The firm invests in specialty pharma, biopharmaceuticals, medical devices, and diagnostics, managing over €425M across multiple funds, typically leading or co-leading investment syndicates and targeting exits within 3 to 6 years of initial investment.

Product overview

Fountain Healthcare Partners is a venture capital fund that provides risk capital and expertise to entrepreneurs building life sciences companies. The firm invests across specialty pharma, biopharmaceuticals, medical devices, and diagnostics sectors, focusing on seed and early-stage investments in Europe and the United States. Rather than offering a traditional product suite, the firm manages investment funds and provides expertise to its portfolio companies. The firm's investment strategy targets companies with potential for significant exit within 3 to 6 years of initial investment, with over €425M under management.

Differentiator

Problem solved

Functional benefit

Products and services

• Fountain Healthcare Partners Investment Funds

Quantifiable outcome

• Multiple successful exits including acquisitions by Bayer, Roche, Novartis, AbbVie, Johnson & Johnson, and others with cumulative value exceeding $1.5B

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Andera Partners: Paris-based private equity firm with a dedicated life sciences arm (Andera Life Sciences); comparable as a European biopharma specialist and co-investor with Fountain in Exciva.
• Gimv: Belgian-listed European investment firm with a healthcare and life sciences platform; comparable as a mid-market European specialist with biopharma and medtech exposure that co-invested in Exciva's Series B.
• HealthCap: Stockholm-based life sciences VC manager focused on therapeutics and medical technology; comparable in mandate and stage focus to Fountain's European specialist strategy.
• MVM Partners: Boston/London healthcare-focused growth equity firm investing across medical technology, biopharma, and diagnostics; comparable as a healthcare specialist co-investor with Fountain in Neurent Medical and XyloCor Therapeutics.
• Sofinnova Partners: Paris-based European life science venture capital firm investing across biopharma and medtech stages; directly comparable to Fountain as a specialist life sciences investor and frequent co-investor (e.g., Neurent Medical Series C).
• EQT Life Sciences: Amsterdam-based life sciences investor (formerly LSP), part of EQT Group; comparable as a European-anchored specialist VC across biopharma, medtech, and digital health with strong follow-on capacity; co-invests with Fountain in Neurent and Exciva.
• Forbion: Dutch life sciences VC investing across early- and late-stage biopharma and medtech; comparable as a European specialist with a similar transatlantic investment remit and fund size tier to Fountain.
• Atlantic Bridge: Dublin-based growth equity firm investing across deep tech and life sciences with a transatlantic platform; directly comparable as an Irish-anchored VC with European and US deal flow that co-invests alongside Fountain.

Broad incumbents

• SR One (GSK): GlaxoSmithKline's corporate venture arm investing across biopharma and medtech globally; comparable as a deep-pocketed life sciences investor with similar therapeutic focus, though backed by a strategic corporate parent rather than independent LPs.

Emerging players

• Jeito Capital: Paris-based healthcare-dedicated growth equity firm launched in 2020; comparable as a focused life sciences investor and co-lead in XyloCor's $67.5M Series B, though typically later-stage than Fountain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments56 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fountain Healthcare Partners